Plaza Z, Soriano V, Vispo E, et al.Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.Antivir Ther2012; 17: 921–926.
2.
LeggewieM., SreenuV.B., AbdelrahmanT.Natural NS3 resistance polymorphisms occur frequently prior to treatment in HIV-positive patients with acute hepatitis C.AIDS2013; 27: 2485–2488.
3.
WebsterD.P., WojcikiewiczT., KellerM.Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin.Int J STD AIDS2013; 24: 179–183.
4.
FiererD.S., DieterichD.T., MullenM.P.Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.Clin Infect Dis2014; 58: 873–879.
5.
SulkowskiM.S., ShermanK.E., DieterichD.T.Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.Ann Intern Med2013; 159: 86–96.
6.
SulkowskiM., PolS., MallolasJ.Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled Phase 2 trial.Lancet Infect Dis2013; 13: 597–605.
7.
LawitzE., GaneE.J.Sofosbuvir for previously untreated chronic hepatitis C infection.N Engl J Med2013; 369: 678–679.
8.
BeldaO., Targett-AdamsP.Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.Virus Res2012; 170: 1–14.
9.
KowdleyK.V., LawitzE., PoordadF.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.N Engl J Med2014; 370: 222–232.
10.
FrancoS., CasadellàM., Noguera-JulianM.No detection of the NS5B S282T mutation in treatment-naive genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.J Clin Virol2013; 58: 726–729.
11.
PalanisamyN., DanielssonA., KokkulaC.Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a.Antiviral Res2013; 99: 12–17.
12.
FridellR.A., WangC., SunJ-HGenotype and phenotypic analysis of variants resistant to hepatitis C virus non-structural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.Hepatology2011; 54: 1924–1935.
13.
BartelsD.J., ZhouY., ZhangE.Z.Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.J Infect Dis2008; 198: 800–807.
14.
TreviñoA., de MendozaC., ParraP.Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.Antivir Ther2011; 16: 413–416.
15.
BartelsD.J., SullivanJ.C., ZhangE.Z.Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAA) were rarely observed in DAA-naive patients prior to treatment.J Virol2013; 87: 1544–1553.
